cancer break through AnaptysBio (ANAB) created Jemperli by using its proprietary somatic hypermutation (SHM) antibody platform. It was further developed by Tesaro, which is now a part of GlaxoSmithKline (GSK) under collaboration. While Jemperli was ANAB’s first antibody to receive approval, the company has multiple therapeutic antibodies under development.
The drug is also being evaluated for multiple tumor types and cancers. These include platinum-resistant ovarian cancer, non-small cell lung cancer, multiple myeloma, and melanoma. GSK is also developing additional antibodies with ANAB, and the latter can receive about $1.1 billion in aggregate milestone payments under the collaboration. Future royalties to ANAB on Jemperli sales range from 8% to 25% of global net sales.
In comparison, the market capitalization of ANAB currently stands at $558.6 million and it had a cash balance of $597 million at the end of the first quarter.
Market Data 
Markets 
AI
